Maria Gabriela Raso

Assistant Professor

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Maria Gabriela Raso is an Assistant Professor at the University of Texas MD Anderson Cancer Center in the United States. Her research primarily focuses on cancer therapeutics, particularly the efficacy of novel treatments such as ATR kinase inhibitors and antibody-drug conjugates in various tumor types. Recent publications highlight her work in biomarker analysis, the tumor microenvironment, and the role of signaling pathways in cancer progression.

Articles (13)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2020

Collaborators (4)

Hind Rafei

Assistant Professor of Medicine

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Rafet Basar

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

J. Jack Lee

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Jiexin Zhang

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Maria Gabriela Raso

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations

Antitumor Activity and Biomarker Analysis for TROP2 Antibody–Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models

CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis

Heterogeneous Profile of ROR1 Protein Expression across Tumor Types

Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts

Translational Aspects in Metaplastic Breast Carcinoma

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers

STAT3 protects HSCs from intrinsic interferon signaling and loss of long-term blood-forming activity

Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights

Chronic Exposure to Waterpipe Smoke Elicits Immunomodulatory and Carcinogenic Effects in the Lung

Pathology and Classification of SCLC

PI4KIII beta is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma

Collaborators (4)

Hind Rafei

Rafet Basar

J. Jack Lee

Jiexin Zhang

Make your next move.